Unlock this StockReport nowClick to Unlock

Vectura Share Price

VEC 81.05p -2.7  -3.2%
4:40pm 30.0k
StockRank

Momentum
Relative Strength (%)
1m
3m
1yr
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
vs.
market
vs.
industry
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
PEG x
Profitability
Operating Margin %
ROA %
ROCE %
ROE %
Cashflow
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividends
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p +5.5%

FINANCIAL BRIEF: For the fiscal year ended 31 December 2018, Vectura Group PLC revenues increased 8% to £160.5M. Net loss before extraordinary items increased 1% to £88.2M. Revenues reflect United Kingdom segment increase of 12% to £55.2M, Switzerland segment increase of 14% to £31M. Higher net loss reflects Impairment of Intangibles Excl Goodwill increase from £8.7M to £41.5M (expense), Legal Fees increase from £1.8M to £7.1M (expense). more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
E+
E+
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
vs.
market
vs.
industry
Recent History
Latest interim period (ended 31st Dec '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2019
31st Dec 2020

Price Target: 1.14
(+36.71% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
7 brokers Broker Consensus Trend
Broker Recommendations for Vectura
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 3 4 4

Named Brokers and Analysts
Stifel Nicolaus and Company, Incorporated Max Herrmann , RBC Capital Markets Zoe Karamanoli , Citi Joanne Jerman , Investec Bank (UK) Plc Andrew Whitney , Panmure Gordon Julie Simmonds , Numis Securities Stefan Hamill , Peel Hunt Amy Walker , Edison Investment Research Andy Smith , JPMorgan James Gordon , N+1 Singer Jens Lindqvist , Shore Capital Stockbrokers Adam Barker , Cantor Fitzgerald Europe Brian White , Rx Securities Samir Devani ,

Profile Summary

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Directors: James Ward-Lilley (CEO) 51, Paul Fry (CEO) , Joanne Hombal (EVP) , Antony Fitzpatrick (EVP) , Roger Heerman (EVP) 43, David Lescuyer (EVP) , Gonzalo Miquel (EVP) , Geraldine Venthoye (EVP) , John Murphy (GCN) 62, Bruno Angelici (NEC) 72, Per-Olof Andersson (NED) 65, Juliet Thompson (NED) 52, Thomas Werner (NED) 63, Susan Foden (NID) ,

No. of Employees: 453 No. of Shareholders: n/a


Last Annual December 31st, 2018
Last Interim December 31st, 2018
Incorporated August 13, 1997
Public Since July 2, 2004
Shares in Issue 665,576,371
Free Float 614.3m (92.3%)

VEC Share Price Performance VEC Share Price Quote
81.05p
-2.7  -3.2%
Traded 4:40pm · Minimum 15 min delayed · NMS: 30.0k

Latest VEC News Announcements (delayed)

Upcoming VEC Events

Recent ↓
Wednesday 29th May, 2019
Vectura Group PLC Annual Shareholders Meeting
Tuesday 26th March, 2019
Full Year 2018 Vectura Group PLC Earnings Call
Thursday 10th January, 2019
Vectura Group PLC at JPMorgan Global Healthcare Conference
Monday 26th November, 2018
Vectura Group plc - Special Call
Thursday 8th November, 2018
Vectura Group plc - Special Call
Tuesday 11th September, 2018
Half Year 2018 Vectura Group PLC Earnings Call
Tuesday 21st August, 2018
Vectura Group plc - Special Call
Wednesday 21st March, 2018
Full Year 2017 Vectura Group PLC Earnings Call
Wednesday 10th January, 2018
Vectura Group PLC at JPMorgan Healthcare Conference
Thursday 4th January, 2018
Full Year 2017 Vectura Group PLC Corporate Sales Call
Wednesday 6th September, 2017
Q2 2017 Vectura Group PLC Earnings Call
Wednesday 6th September, 2017
Half Year 2017 Vectura Group PLC Earnings Release
Wednesday 28th June, 2017
Vectura Group PLC Capital Markets Event
Tuesday 21st March, 2017
Full Year 2016 Vectura Group PLC Earnings Call
Tuesday 21st March, 2017
Full Year 2017 Vectura Group PLC Earnings Call
Tuesday 21st March, 2017
Full Year 2016 Vectura Group PLC Earnings Release
Wednesday 11th January, 2017
Vectura Group PLC at JPMorgan Healthcare Conference
Wednesday 23rd November, 2016
Half Year 2016 Vectura Group PLC Earnings Call
Wednesday 23rd November, 2016
Half Year 2016 Vectura Group PLC Earnings Release
Wednesday 7th September, 2016
Vectura Group PLC Annual Shareholders Meeting


Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.


Should you buy VEC

Access VEC Analytics Now!

FREE TRIAL or TAKE THE TOUR
Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis